BRIDGEWATER, N.J., Nov. 8, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:
- The Stifel 2023 Healthcare Conference in New York on Tuesday, November 14, 2023, at 8:00 a.m. ET in a fireside chat
- The 6th Annual Evercore ISI HealthCONx Conference in Miami on Wednesday, November 29, 2023, at 11:15 a.m. ET in a fireside chat
Each fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of the live event.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more.
Executive Director, Investor Relations
Associate Director, Investor Relations
Executive Director, Corporate Communications
SOURCE Insmed Incorporated